Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation

Area of Science:

• Immunology
• Hematology
• Epigenetics

Background:

• Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders with a high risk of progressing to acute myeloid leukemia.
• Somatic mutations, particularly in the epigenetic regulator TET2, are frequently observed in MDS.
• Natural Killer (NK) cells are crucial for anti-leukemic immune responses due to their cytolytic activity.

Purpose of the Study:

• To investigate the impact of TET2 mutations on NK cell function in MDS patients.
• To explore the phenotypic and functional consequences of TET2 mutations in NK cells.
• To assess the potential of therapeutic interventions like azacitidine in restoring NK cell function.

Main Methods:

• Analysis of phenotypic defects in circulating NK cells from MDS patients with TET2 mutations.
• Genotyping of NK cells and MDS clones to confirm shared TET2 status.
• In vitro inhibition of TET2 in healthy donor NK cells to assess functional impact.
• Evaluation of NK cell function (KIR, perforin, TNF-α, cytotoxicity, IFN-γ) in patients before and after azacitidine treatment.

Main Results:

• MDS patients with TET2 mutations exhibit distinct NK cell phenotypes.
• NK cells and MDS clones share the TET2 genotype.
• TET2-mutated NK cells show increased DNA methylation and reduced expression of KIR, perforin, and TNF-α.
• In vitro TET2 inhibition impairs NK cell cytotoxicity.
• Azacitidine treatment in MDS patients enhances KIR and cytolytic protein expression and IFN-γ production.

Conclusions:

• TET2 mutations in MDS contribute to impaired NK cell function, compromising anti-leukemic immunity.
• NK cell dysfunction in MDS is linked to epigenetic alterations driven by TET2 mutations.
• Azacitidine shows promise in restoring NK cell function and potentially enhancing anti-leukemic responses in MDS patients.